AgelessRx received $1 million in XPRIZE funding to conduct a one-year randomized controlled trial testing a multi-component intervention—combining low-dose naltrexone, metformin, NAD+, B12, rapamycin, glutathione, and proprietary supplement with exercise and meditation—on muscle, cognitive, and immune function in adults aged 50 to 90. The trial represents a shift toward rigorous human testing of combination therapies designed to address multiple aspects of healthspan rather than single-target interventions.
Key Points
- Multi-component regimen targets muscle, cognition, immunity simultaneously
- Pilot of 26 subjects completed; full trial enrolls 186 subjects 2026-2029
- University of Utah and UC San Diego coordinating biomarker standardization
Longevity Analysis
This trial addresses a critical gap in human evidence for combination interventions that work across multiple physiological domains. Most longevity research isolates single compounds; testing them together reflects how the body actually functions—as integrated systems where energy production, defense capacity, nervous system resilience, and muscle maintenance interconnect. The inclusion of structured exercise and meditation alongside pharmacologic agents recognizes that chemical support alone, without behavioral consistency and nervous system regulation, produces incomplete results. The three-year timeline and standardized biomarker coordination across two major research institutions signal a maturation in how combination protocols are validated, moving beyond small pilot data into clinically interpretable evidence that practitioners and patients can assess for safety and efficacy.
Original published by LT Wire.